Kenneth Evan Thompson

Title: Innovations of Kenneth Evan Thompson

Introduction

Kenneth Evan Thompson is a notable inventor based in Arlington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 5 patents to his name, Thompson's work has the potential to impact cancer treatment and vaccine efficacy.

Latest Patents

Thompson's latest patents include innovations related to Anti-KLRG1 antibodies. These inventions focus on antibodies that specifically bind to the killer cell lectin-like receptor G1 (KLRG1). Such antibodies are useful for various therapeutic and diagnostic purposes, including the treatment of cancers and enhancing the effectiveness of vaccines. Another significant patent involves methods of treating disorders associated with excess or unwanted KLRG1 expressing T cells using KLRG1 depleting antibodies. This work highlights the discovery and characterization of antibodies that bind to the extracellular domain of KLRG1 without interfering with its interaction with ligands such as E-cadherin, N-cadherin, and R-cadherin. The antibodies derived from mouse hybridoma technology can be humanized, making them effective therapeutic agents.

Career Highlights

Throughout his career, Kenneth Evan Thompson has worked with prestigious organizations, including The Brigham and Women's Hospital, Inc. and Abcuro, Inc. His contributions to these institutions have furthered research in the field of immunology and therapeutic development.

Collaborations

Thompson has collaborated with notable colleagues such as Stefano V Gulla and Harold F Guerndt, Jr. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

Kenneth Evan Thompson's innovative work in the field of biotechnology, particularly with KLRG1 antibodies, showcases his dedication to advancing medical science. His contributions have the potential to significantly improve therapeutic options for patients.